Taxane plus platinum regimens may be a reasonable alternative to doxorubicin plus cisplatin as postoperative adjuvant chemotherapy for endometrial cancer that carries a high risk for progression, according to a study published online March 21 in JAMA Oncology. Hiroyuki Nomura, M.D., from the Keio University School of Medicine in Tokyo, and colleagues evaluated the clinical benefit of taxane plus platinum regimens as postoperative adjuvant chemotherapy for patients with endometrial cancer (high-risk stage I to II or stage III to IV that did not extend beyond the abdominal cavity and had a residual tumor of 2 cm or larger).

Beyond the abdominal cavity

Patients were randomly assigned to receive six cycles of doxorubicin plus cisplatin (263 participants), docetaxel plus cisplatin (263), or paclitaxel plus carboplatin (262) on day 1 every three weeks. Because The researchers found that tolerability of the regimens did not differ statistically. After a median follow-up period of seven years, there was no statistical difference among the groups for progression-free survival (doxorubicin plus cisplatin, 191; docetaxel plus cisplatin, 208; paclitaxel plus carboplatin, 187; P = 0.12) or overall survival (doxorubicin plus cisplatin, 217; docetaxel plus cisplatin, 223; paclitaxel plus carboplatin, 215; P = 0.67).

Five-year progression-free survival rates for doxorubicin plus cisplatin; docetaxel plus cisplatin, and paclitaxel plus carboplatin were 73.3, 79, and 73.9 %, respectively, while the five-year overall survival rates were 82.7, 88.1, and 86.1 %, respectively. “Because each regimen showed adequate tolerability but different toxic effects, taxane plus platinum regimens may be a reasonable alternative to treatment with doxorubicin plus cisplatin;” the authors write.

Including sarcomas

Several authors disclosed financial ties to pharmaceutical companies. Cisplatin, cisplatinum, or cis diamminedi chloro platinum(II) (CDDP) (trade names Platinol and Platinol-AQ) is a chemotherapy drug. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumors. It was the first member of a class of platinum-containing anti-cancer drugs, which now also includes carboplatin and oxaliplatin.

These platinum complexes react in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Because Endometrial cancer is a cancer that arises from theendometrium (the lining of the uterus or womb). It is the result of the abnormal growth of cells that have the ability to invade or spread to other parts of the body. The first sign is most often vaginal bleeding not associated with a menstrual period.

Endometrial cancer

Endometrial cancer is a type of cancer that begins in the uterus. Because The uterus is the hollow; pear-shaped pelvic organ in women where fetal development occurs. Endometrial cancer begins in the layer of cells that form the lining (endometrium) of the uterus. Endometrial cancer is sometimes call uterine cancer. Because  Other types of cancer can form in the uterus, including uterine sarcoma; but they are much less common than endometrial cancer.
Endometrial cancer is often detected at an early stage because it frequently produces abnormal vaginal bleeding; which prompts women to see their doctors. Because If endometrial cancer is discover early, removing the uterus surgically often cures endometrial cancer.